Cervical cancer is recognized as a serious public health problem since it remains one of the most common cancers with a high mortality rate among women despite existing preventative, screening, and treatment approaches. Since Human Papillomavirus (HPV) was recognized as the causative agent, the preventative HPV vaccines have made great progress over the last few years. However, people already infected with the virus require an effective treatment that would ensure long-term survival and a cure. Currently, clinical trials investigating HPV therapeutic vaccines show a promising vaccine-induced T-cell mediated immune response, resulting in cervical lesion regression and viral eradication. Among existing vaccine types (live vector, protein-based, nucleic acid-based, etc.), deoxyribonucleic acid (DNA) therapeutic vaccines are the focus of the study, since they are safe, cost-efficient, thermostable, easily produced in high purity and distributed. The aim of this study is to assess and compare existing DNA therapeutic vaccines in phase I and II trials, expressing HPV E6 and E7 oncoproteins for the prospective treatment of cervical cancer based on clinical efficacy, immunogenicity, viral clearance, and side effects. Five different DNA therapeutic vaccines (GX-188E, VGX-3100, pNGVL4a-CRT/E7(detox), pNGVL4a-Sig/E7(detox)/HSP70, MEDI0457) were well-tolerated and clinically effective. Clinical implementation of DNA therapeutic vaccines into treatment regimen as a sole approach or in combination with conservative treatment holds great potential for effective cancer treatment.
1 August 2021 in International Journal of Infectious Diseases
The aim of this study was to conduct a nationwide high-risk human papillomavirus (HR-HPV) infection genotyping analysis of women attending gynecological clinics. In addition, this study aimed to identify factors that are associated with HR-HPV infection. This was a cross-sectional survey-based study with 759 participants. Demographics, lifestyle, and medical history data was collected with a questionnaire that was filled by gynecologists during patients' visit. Cervical swabs were used as a source for HPV genotyping using AmpliSens kit. Data analysis was carried out which included descriptive statistics consisting of mean values, standard deviations, and frequencies, where applicable. To identify factors associated with HPV infection status, ordinal logistic regression was built. The mean age of the participants was 36.51 ± 10.09 years. The majority of women who participated in this study were aged between 26 and 35 years. Less than half of the women (39%) were HPV positive, 26% of participants had a single HR-HPV and 13% had multiple HR-HPV infections. The most prevalent HR-HPV genotypes were HPV-16 (54%), HPV-51 (7%), HPV-68 (7%), and HPV-18 (6%). The results of ordinal logistic regression demonstrated that factors such as older age, not being single, and having history of sexually transmitted infections (STIs), decrease the odds of having HPV infection. This study identified high prevalence of HR-HPV among Kazakhstani women. Apart from this, our results showed that adding HPV testing to compulsory cervical cancer screening in Kazakhstan could help to improve the screening program and decrease the rates of cervical cancer.
Cervical cancer represents a great burden to public health of women. This study aimed to obtain a nationwide genotyping survey and analysis of high risk-HPV including those that are caused by HPV types other than HPV-16 and HPV-18, among women in Kazakhstan. This study was conducted based on the collection of survey and cervical swabs of 1645 women across the country. The samples were genotyped for high-risk HPV types based on real-time PCR methods. Collected data was analyzed with the focus on high-risk HPV types other than HPV-16 and -18. Infection was present in 22% of women who participated in the study. The most prevalent types were HPV-31 among single infections and HPV-68 among multiple infections. Conclusively, despite the lack of attention high-risk HPV types beyond HPV-16 and -18 get in attempts of cervical cancer prevention in Kazakhstan, their prevalence is high and plays a large role in cervical cancer epidemiological situation.